Alpha Cognition Inc. Common Stock (ACOG) Insider Trading Activity

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Show less

Over the last 12 months, insiders at Alpha Cognition Inc. Common Stock have bought $2.51M and sold $250,002 worth of Alpha Cognition Inc. Common Stock stock.

On average, over the past 5 years, insiders at Alpha Cognition Inc. Common Stock have bought $2.51M and sold $250,002 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Opaleye Management Inc. (10 percent owner) — $2.13M. MERTZ LEONARD POWELL (director) — $250,002. Wills Robert James (director) — $127,328.

The last purchase of 1,850 shares for transaction amount of $9,227 was made by Opaleye Management Inc. (10 percent owner) on 2026‑03‑30.